Valuation: Valeo Pharma Inc.

Market Cap 6.24M 4.43M 3.89M 3.62M 3.33M 423M 6.35M 42.92M 16.8M 210M 16.62M 16.26M 725M P/E 2022
-2.09x
P/E 2023 -0.45x
Enterprise Value 64.5M 45.77M 40.17M 37.41M 34.41M 4.37B 65.6M 444M 174M 2.17B 172M 168M 7.49B EV / Sales 2022
3.37x
EV / Sales 2023 1.35x
Free-Float
52.66%
Yield 2022 *
-
Yield 2023 -
Current year 0
Extreme 0
0
1 year 0
Extreme 0
0
3 years 0
Extreme 0
0.4
5 years 0
Extreme 0
0.84
10 years 0
Extreme 0
1.4
Manager TitleAgeSince
Director of Finance/CFO - 2023-11-19
Chief Tech/Sci/R&D Officer - 2021-05-31
Investor Relations Contact - 2019-05-31
Director TitleAgeSince
Chairman 67 2024-08-05
Chairman 91 2018-07-24
Director/Board Member 67 2022-04-26
Date Insider Type Main position Quantity % Market Cap.
11/11/24 Other

Investor Relations Manager

0 0%
11/11/24 Other

Investor Relations Manager

0 0%
11/11/24 Other

Investor Relations Manager

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 98
+0.07%+4.48%+59.26%+167.32% 1,089B
+0.27%+4.50%+58.91%+59.46% 643B
+1.12%+4.86%+38.91%+77.58% 465B
-1.10%+9.51%+40.27%+34.52% 359B
-0.75%+3.53%+36.99%+42.48% 303B
+1.52%+3.23%+17.51%+17.22% 267B
+0.44%+5.38%-2.94%-38.34% 226B
+0.16%+7.65%+29.81%+68.29% 212B
-0.56%+2.06%+16.45%+74.70% 167B
Average +0.10%+4.57%+32.80%+55.91% 373.11B
Weighted average by Cap. +0.14%+5.14%+42.68%+81.63%

Financials

2022 2023
Net sales 27.74M 19.69M 17.28M 16.09M 14.8M 1.88B 28.22M 191M 74.72M 933M 73.92M 72.33M 3.22B 53.91M 38.26M 33.58M 31.27M 28.76M 3.66B 54.83M 371M 145M 1.81B 144M 141M 6.26B
Net income -25.75M -18.27M -16.04M -14.93M -13.73M -1.75B -26.19M -177M -69.34M -866M -68.6M -67.11M -2.99B -27.81M -19.74M -17.32M -16.13M -14.83M -1.89B -28.28M -191M -74.89M -935M -74.09M -72.49M -3.23B
Net Debt 38.94M 27.64M 24.25M 22.58M 20.77M 2.64B 39.61M 268M 105M 1.31B 104M 102M 4.52B 58.26M 41.35M 36.29M 33.79M 31.08M 3.95B 59.26M 401M 157M 1.96B 155M 152M 6.77B
Logo Valeo Pharma Inc.
Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.
Employees
70

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VPHIF Stock